药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Volociximab
The risk or severity of adverse effects can be increased when Volociximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Catumaxomab
The risk or severity of adverse effects can be increased when Catumaxomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lexatumumab
The risk or severity of adverse effects can be increased when Lexatumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lerdelimumab
The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bivatuzumab
The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sibrotuzumab
The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Siplizumab
The risk or severity of adverse effects can be increased when Siplizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lucatumumab
The risk or severity of adverse effects can be increased when Lucatumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Belantamab mafodotin.